Skyrizi is used to treat certain inflammatory conditions, such as plaque psoriasis. The drug starts working after your first dose. Skyrizi is approved by the Food and Drug Administration (FDA) to ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand advertising on TV in 2024, according to data released by iSpot.tv on Thursday afternoon. AbbVie’s psoriasis, ulcerative colitis, Crohn’s ...

The company’s follow-up drug Skyrizi is a key plank in AbbVie’s strategy to negotiate the $20 billion patent cliff from Humira, which has already seen sales decline outside of the US where it ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

This week also saw a notable surge from pharmaceutical company AbbVie, with their drug Skyrizi, which leaped from 32nd to 4th place. PayPal, T-Mobile, and Vicks also made solid showings ...